COMMUNIQUÉS West-GlobeNewswire

ALR Technologies Announces That Its ALRT Diabetes Solution Has Been Developed to an Enterprise-Scale
14/05/2018
The ALRT Diabetes Solution is an enterprise-scale product that allows healthcare systems to implement best practices for diabetes care on large populations of patients - saving lives and money. “REPRESENTS A FUNDAMENTAL [...]
Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results
14/05/2018
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO ) (“Organovo”) will host a conference call on Thursday, May 31, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal [...]
Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology
14/05/2018
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP [...]
FDA Grants Fast Track Designation for Yamo Pharmaceutical’s L1-79 in Autism Spectrum Disorder
14/05/2018
New York, May 14, 2018 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC , a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced today that the US Food and Drug [...]
Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome
14/05/2018
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO ), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Sun BioPharma Provides Business Update and Files Report for Q1 2018
14/05/2018
Enrollment of the First Patient in the Front-Line Combination Study of SBP-101 with Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Expected in May 2018 Data from the Company’s Phase 1 [...]
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results
14/05/2018
-- U.S. Food and Drug Administration (FDA) Agreed that Bardet-Biedl Syndrome (BBS) and Alström Syndrome are Included Under Existing Breakthrough Therapy Designation (BTD) for Setmelanotide -- -- Entered Licensing [...]
Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
14/05/2018
EMERYVILLE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that [...]
Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation
14/05/2018
PARIS, Ontario, May 14, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSX-V: EMC ) (TSX-V:EMC.WT) (“Emblem” or the "Company") and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of [...]
IntelGenx Announces Settlement of Suboxone® Patent Litigation
14/05/2018
SAINT LAURENT, Quebec, May 14, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX ) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that all patent litigation between the Company, Par Pharmaceutical, Inc [...]
RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15
14/05/2018
Last patient completed treatment for primary endpoint assessment in the Phase III study with RHB-104 for Crohn’s disease; Top-line results expected to be announced in approximately 3 months TEL-AVIV, Israel and RALEIGH [...]
Oxford Performance Materials and JSR Corporation Announce Partnership to Advance OPM Technology Platform Throughout Asia
14/05/2018
OPM Subsidiary to Establish Japanese Operation to Manufacture and Market OsteoFab® 3D Printed Implants and OXPEKK® Biomedical Materials SOUTH WINDSOR, Conn. and TOKYO, May 14, 2018 (GLOBE NEWSWIRE) -- Oxford Performance [...]
Avalon GloboCare Provides First Quarter 2018 Business Update; Reports 365% Increase in Revenues and Progress Towards Commercialization of its Cell-Based Technologies
14/05/2018
FREEHOLD, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB:AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a business update for the first [...]
Mateon Therapeutics Reports First Quarter 2018 Financial Results
14/05/2018
SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today [...]
Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286%
14/05/2018
Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, Conn., May 14, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, [...]
Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018
14/05/2018
Zug, Switzerland, May 14, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced that it [...]
Cannabis Wheaton Announces Exclusive License for Dixie Brands’ Cannabinoid-Infused Products in Canada and Mexico
14/05/2018
VANCOUVER, British Columbia, May 14, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX-V: CBW ) (“ Cannabis Wheaton ” or the “ Company ”) is pleased to announce that it has entered into a definitive licensing [...]
VitalHub Introduces Harm Reduction Software
14/05/2018
TORONTO, May 14, 2018 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV:VHI) is pleased to announce the introduction of a harm reduction module, aimed at the growing opioid epidemic facing North [...]
New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics
14/05/2018
CAMBRIDGE, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced new [...]

Pages